{"id":"W4399519971","doi":"10.1200/jco.2024.42.16_suppl.6502","title":"Updated safety and efficacy data from the phase 3 MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve patients with myelofibrosis.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Internal medicine; Phases of clinical research; Oncology; Clinical trial; Surgery; Bone marrow","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004063307,0.0007749958,0.001835595,0.0004427875,0.0003427195,0.0009604787,0.0008221759,0.001000379,0.006491178],"category_scores_gemma":[0.003243246,0.000448193,0.00149428,0.0007167134,0.0003449928,0.0009701567,0.000340674,0.002026292,0.001029165],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005657579,"about_ca_system_score_gemma":0.0009351064,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007340075,"about_ca_topic_score_gemma":0.002236567,"domain_scores_codex":[0.9989161,0.0006312826,0.0001036611,0.0000925257,0.0001699719,0.00008644682],"domain_scores_gemma":[0.9970409,0.0008314067,0.001249727,0.0002099871,0.0002789919,0.0003889721],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6901358,0.009841898,0.03612341,0.004009121,0.007976678,0.0005487927,0.0002984417,0.003507191,0.03466751,0.0003790462,0.03273474,0.1797773],"study_design_scores_gemma":[0.6039653,0.1759453,0.1717686,0.0004988909,0.009195245,0.001631704,0.0001358427,0.001723291,0.004656607,0.0005735183,0.02978709,0.0001186101],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9143201,0.03008401,0.002225457,0.002262868,0.0003663766,0.003104046,0.03775417,0.0005308672,0.009352182],"genre_scores_gemma":[0.9434071,0.006510362,0.002067355,0.002759943,0.0003540174,0.002194513,0.03993579,0.00008060818,0.002690236],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006491178,"threshold_uncertainty_score":0.02171516,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1175971088549572,"score_gpt":0.4558508415527777,"score_spread":0.3382537326978204,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}